Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicorandil is a small molecule antianginal drug used primarily for the prevention and treatment of chronic stable angina pectoris. It acts as both a potassium channel opener (specifically ATP-sensitive potassium channels) and a nitrate donor. Through these dual mechanisms, nicorandil causes vasodilation of both arterial and venous vessels—relaxing vascular smooth muscle to increase coronary blood flow and reduce cardiac preload and afterload. The activation of ATP-sensitive potassium channels leads to hyperpolarization of smooth muscle cells, while the nitrate moiety increases cyclic GMP levels via stimulation of guanylate cyclase, further promoting vasodilation. Nicorandil is typically prescribed when other heart medicines are ineffective or unsuitable[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicorandil.